West-ward Pharmaceutical
Executive Summary
Generic firm is cleared by FDA on March 30 for ANDA approvals following a two-year effort to bring its manufacturing into compliance with Good Manufacturing Practices. A consent decree entered into by West-ward and FDA in January 1992, which led to a temporary shutdown of production at the company's Eatontown, N.J. plant ('The Pink Sheet" Jan. 20, 1992, T&G-15), has been vacated. West-ward said it has filed two ANDAs and two major supplements with the agency and plans to file four ANDAs for eight dosage strengths by the end of 1994